Venlafaxine XR

ApprovedSmall molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Venlafaxine XR is one of 156 small molecule programs targeting Major Depressive Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

155

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Generalized Anxiety DisorderActive, not recruiting

Spinal Cord InjuryActive, not recruiting

Treatment Resistant DepressionActive, not recruiting

Major Depressive DisorderApproved

Active, not recruiting

Generalized Anxiety DisorderPhase 3

Active, not recruiting

Spinal Cord InjuryApproved

Active, not recruiting

Treatment Resistant DepressionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Ketalar

Boehringer Ingelheim

Phase 3

3 3

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 4

Venlafaxine XR

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 5

Psilocybin

COMPASS Pathways

Phase 3

11 6

Bupropion XL

GSK

Phase 3

1 7

ALKS 37

AAlkermes, Inc.

Phase 3

6 8

Aticaprant

Johnson & Johnson

Phase 3

4 9

NBI-1065845

Neurocrine Biosciences

Phase 3

6 10

Second-Line Antipsychotics

DDr. Inge Winter

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder4 trials

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Completed· Otsuka logo

Otsuka·Phase 3·NCT01360866·2,944 enrolled

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

Terminated· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01114698·12 enrolled

Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients

Terminated·MMinistry of Health & Welfare, Korea·Phase 4·NCT00926835·692 enrolled

Show 1 more trial

Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)

Completed·MMassachusetts General Hospital·Approved·NCT02977299·278 enrolled

Generalized Anxiety Disorder3 trials

Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT00151450·390 enrolled

Combined Treatment for Generalized Anxiety Disorder (GAD)

Completed·UUniversity of Pennsylvania·Phase 2·NCT00620776·69 enrolled

Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

Completed·UUniversity of Pennsylvania·Phase 4·NCT00183274·268 enrolled

Depression2 trials

International Study to Predict Optimised Treatment - in Depression

Unknown status·BBRC Operations Pty. Ltd.·Phase 4·NCT00693849·2,688 enrolled

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

Completed·—·Phase 4·NCT02407704·31 enrolled

Trial1 trial

Results From a 24 Week Trial of EMDR Combined With Venlafaxine XR

Withdrawn·—·Phase 4·NCT02433353

Treatment Resistant Depression1 trial

Buprenorphine Used With Treatment Resistant Depression in Older Adults

Completed·WWashington University School of Medicine·Phase 1/2·NCT02181231·18 enrolled

7 more indications

Spinal Cord Injury1 trial

Project to Improve Symptoms and Mood in People With Spinal Cord Injury

Completed·UUniversity of Washington·Phase 4·NCT00592384·133 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177528·70 enrolled

Major Depression1 trial

A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00644982·163 enrolled

Depressed1 trial

Study Evaluating Venlafaxine Extended-Release in Depressed and Anxious Patients

Completed· Pfizer logo

Pfizer·Phase 4·NCT00546923·210 enrolled

Hydrocortisone1 trial

Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?

Completed·SStanford University·N/A·NCT00186264·18 enrolled

Menopausal Symptoms1 trial

MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms

Completed·FFred Hutchinson Cancer Center·N/A·NCT01418209·339 enrolled

Unspecified1 trial

Sertraline vs. Venlafaxine XR

Completed·VVanderbilt University·Phase 3·NCT00179283·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Venlafaxine XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Venlafaxine XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Venlafaxine XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Venlafaxine XR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder4 trials

Generalized Anxiety Disorder3 trials

Depression2 trials

Trial1 trial

Treatment Resistant Depression1 trial

Spinal Cord Injury1 trial

Safety and Efficacy1 trial

Major Depression1 trial

Depressed1 trial

Hydrocortisone1 trial

Menopausal Symptoms1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News